Bristol/NeuroSearch dopamine reuptake inhibitor collaboration could net Danish firm up to $29 mil.
BRISTOL/NEUROSEARCH PARKINSON's COLLABORATION COULD NET NEUROSEARCH $29 MIL. in upfront and milestone payments, the companies announced Jan. 17. Bristol-Myers Squibb will work with the Danish firm NeuroSearch A/S to develop NeuroSearch's NS2214, a dopamine reuptake inhibitor. BMS will pay NeuroSearch royalties on sales of the compound.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth